Key Market Indicators
Sales of Australian antirheumatic medicines are forecast to reach $65 million by 2026, down 1.9% annually from $75 million in 2021. Since 1995, the market has declined by an average of 2.7% per year. In 2021, Australia ranked tenth, with Sweden in the lead at $75 million. Germany, Spain, and Canada followed in second, third, and fourth place, respectively.